acActos Lawsuit: There is a very close relationship between survival of an individual and the stage of bladder cancer at diagnosis. For superficial disease, five year survival rates are greater than 90%. Once the cancer has spread into the bladder muscle and beyond, survival is markedly reduced. Five year survival in those with T2 disease (tumor invading superficial bladder muscle) is 60-75%, T3 disease (tumor invading deep muscle) 36-58%, and for those with T4 disease (tumor invading surrounding organs) or with node positive disease, 4-35%.’ With distant (metastatic) spread, survival at five years is less than 5%.
Most individuals with bladder cancer will undergo an initial removal of their bladder tumor by biopsy or for larger tumors by resection of their tumor via a resectoscope. For complete details see Chapter 8. Once this tumor is removed, the pathologist will determine and report on the extent of tumor invasion into the wall of the bladder. If the tumor has grown into the prostate, tissue removal via the resectoscope from this location will also be reviewed and reported pathologically. This pathologic diagnosis determines the initial stage of the cancer.
When dealing with large tumors after the initial cancer resection, your urologist may do a manual exam under anesthesia. By pressing deeply on the pelvis, the urologist may be able to palpate the tumor and assess its possible spread beyond the bladder. With modern technology and the availability of the CT scan, the manual exam is now of less importance. The CT scan can often visualize a thickened or distorted bladder wall, indicating the possibility of tumor involvement or extension through the wall. More importantly, it can determine spread to adjacent organs or lymph node involvement. Distant spread into the abdomen or beyond may also be seen. Other studies, such as the Bone Scan or Chest X ray can assess the presence and extent of metastatic diseases, MRI can be used for those with limited kidney function that cannot have a CT scan. More recently, Positron Emission Tomography (PET) scan has become available. This study can sometimes locate small deposits of metastatic disease not visible on CT or MRI scan.
Our use of the term or terms Actos Lawsuit is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.
Actos Lawsuit